Total Payments
$19,475
2024 Payments
$1,250
Companies
4
Transactions
36
Medicare Patients
987
Medicare Billing
$121,623
Payment Breakdown by Category
Research$18,076 (92.8%)
Other$1,250 (6.4%)
Food & Beverage$149.21 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18,076 | 33 | 92.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,250 | 1 | 6.4% |
| Food and Beverage | $149.21 | 2 | 0.8% |
Payments by Type
Research
$18,076
33 transactions
General
$1,399
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $12,001 | 20 | $0 (2023) |
| GENZYME CORPORATION | $6,000 | 13 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,325 | 1 | $0 (2021) |
| JAZZ PHARMACEUTICALS INC. | $149.21 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,250 | 1 | GENZYME CORPORATION ($1,250) |
| 2023 | $2,844 | 5 | GENZYME CORPORATION ($1,500) |
| 2022 | $12,130 | 22 | Regeneron Pharmaceuticals, Inc. ($9,630) |
| 2021 | $3,102 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($1,325) |
| 2019 | $41.39 | 1 | JAZZ PHARMACEUTICALS INC. ($41.39) |
| 2018 | $107.82 | 1 | Jazz Pharmaceuticals Inc. ($107.82) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,250.00 | General |
| Category: Immunology | ||||||
| 11/15/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) • Category: Immunology | ||||||
| 11/15/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) • Category: Immunology | ||||||
| 08/31/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) • Category: Immunology | ||||||
| 08/31/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) • Category: Immunology | ||||||
| 08/01/2023 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $1,344.38 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/01/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $734.55 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/01/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $734.55 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/01/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $282.83 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/01/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $282.83 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/01/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $54.22 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/01/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $39.89 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/01/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $1,433.18 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/01/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $1,273.93 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/01/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $429.83 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/01/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $429.83 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/01/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $429.83 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 06/02/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $652.93 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 06/02/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) • Category: Immunology | ||||||
| 06/02/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $250.00 | Research |
| Study: A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) • Category: Immunology | ||||||
| 06/01/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) • Category: Immunology | ||||||
| 03/25/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $1,162.80 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/25/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) • Category: Immunology | ||||||
| 03/25/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) • Category: Immunology | ||||||
| 03/14/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $251.40 | Research |
| Study: DUPIXENT CLINICAL DEVELOPMENT PROGRAM • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $12,001 | 20 |
| A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) | GENZYME CORPORATION | $4,750 | 12 |
| A STUDY TO ASSESS THE FREQUENCY AND CHARACTERISTICS OF WAKE AND SLEEP STATE TRANSITIONS OVER MULTIPLE NIGHTS IN SUBJECTS WITH NARCOLEPSY TYPE 1 COMPARED WITH HEALTHY SUBJECTS USING A PORTABLE ELECTROENCEPHALOGRAM DEVICE | Takeda Pharmaceuticals U.S.A., Inc. | $1,325 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 221 | 283 | $123,555 | $31,205 |
| 2022 | 8 | 245 | 294 | $166,389 | $30,093 |
| 2021 | 4 | 166 | 221 | $192,998 | $26,231 |
| 2020 | 7 | 355 | 404 | $225,929 | $34,094 |
Total Patients
987
Total Services
1,202
Medicare Billing
$121,623
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 74 | 105 | $54,460 | $14,203 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 50 | 50 | $38,620 | $9,011 | 23.3% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 24 | 24 | $11,280 | $2,523 | 22.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $11,660 | $2,513 | 21.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 34 | 65 | $4,875 | $1,847 | 37.9% |
| G0398 | Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation | Office | 2023 | 19 | 19 | $2,660 | $1,109 | 41.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 66 | 80 | $55,008 | $9,798 | 17.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 30 | 40 | $36,240 | $5,147 | 14.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $16,542 | $3,676 | 22.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $12,100 | $2,884 | 23.8% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 17 | 17 | $20,128 | $1,758 | 8.7% |
| G0398 | Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturation | Office | 2022 | 30 | 30 | $4,200 | $1,721 | 41.0% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2022 | 16 | 17 | $7,990 | $1,655 | 20.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 18 | 41 | $3,075 | $1,222 | 39.7% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2022 | 11 | 11 | $5,390 | $1,218 | 22.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 12 | 13 | $5,716 | $1,014 | 17.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 57 | 83 | $72,198 | $9,872 | 13.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 42 | 71 | $63,576 | $9,023 | 14.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 20 | 20 | $20,080 | $2,727 | 13.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $12,048 | $2,103 | 17.5% |
| 95810 | Sleep monitoring of patient (6 years or older) in sleep lab | Office | 2021 | 17 | 17 | $20,128 | $1,860 | 9.2% |
| 95800 | Study of sleep patterns, including sleep time | Office | 2021 | 18 | 18 | $4,968 | $645.49 | 13.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 51 | 78 | $50,954 | $7,828 | 15.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 27 | 41 | $25,070 | $3,924 | 15.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 25 | 25 | $12,813 | $3,905 | 30.5% |
About Dr. Emmanuel During, MD
Dr. Emmanuel During, MD is a Sleep Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2011. The National Provider Identifier (NPI) number assigned to this provider is 1104110212.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Emmanuel During, MD has received a total of $19,475 in payments from pharmaceutical and medical device companies, with $1,250 received in 2024. These payments were reported across 36 transactions from 4 companies. The most common payment nature is "" ($18,076).
As a Medicare-enrolled provider, During has provided services to 987 Medicare beneficiaries, totaling 1,202 services with total Medicare billing of $121,623. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Sleep Medicine
- Other Specialties Psychiatry, Neurology
- Location New York, NY
- Active Since 06/06/2011
- Last Updated 07/13/2022
- Taxonomy Code 207RS0012X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1104110212
Products in Payments
- DUPIXENT (Biological) $18,001
- Xyrem (Drug) $107.82
- XYREM (Drug) $41.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Sleep Medicine Doctors in New York
Dr. Omar Burschtin, M.d, M.D
Sleep Medicine — Payments: $70,610
Sleep Medicine $70,610
Mayank Shukla
Sleep Medicine — Payments: $65,430
Sleep Medicine $65,430
Mr. Daniel Barone, M.d, M.D
Sleep Medicine — Payments: $43,668
Sleep Medicine $43,668
Dr. Carl Bazil, M.d, Ph.d, M.D, PH.D
Sleep Medicine — Payments: $24,150
Sleep Medicine $24,150
Dr. Vincent Grbach, Md, MD
Sleep Medicine — Payments: $20,801
Sleep Medicine $20,801
Dr. Andrew Varga, Md/Phd, MD/PHD
Sleep Medicine — Payments: $14,530
Sleep Medicine $14,530